INHIBET Trademark

Trademark Overview

On Tuesday, November 9, 2021, a trademark application was filed for INHIBET with the United States Patent and Trademark Office. The USPTO has given the INHIBET trademark a serial number of 97115230. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Wednesday, November 6, 2024. This trademark is owned by VYNE Therapeutics Inc.. The INHIBET trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treating inflammatory disorders or diseases, autoimmune disorders or diseases, and related disorders or diseases; topical pharmaceutical preparations for treating inflammatory disorders or diseases, autoimmune disorders or diseases, and related disorders or diseases; pharmaceutical preparations for systemic application including by oral administration or by injection for treating inflammatory disorders or diseases, autoimmune disorders or diseases, and related disorders or diseases
inhibet

General Information

Serial Number97115230
Word MarkINHIBET
Filing DateTuesday, November 9, 2021
Status645 - FINAL REFUSAL - MAILED
Status DateWednesday, November 6, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for treating inflammatory disorders or diseases, autoimmune disorders or diseases, and related disorders or diseases; topical pharmaceutical preparations for treating inflammatory disorders or diseases, autoimmune disorders or diseases, and related disorders or diseases; pharmaceutical preparations for systemic application including by oral administration or by injection for treating inflammatory disorders or diseases, autoimmune disorders or diseases, and related disorders or diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 17, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameVYNE Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBridgewater, NJ 08807

Trademark Events

Event DateEvent Description
Friday, November 12, 2021NEW APPLICATION ENTERED
Wednesday, November 17, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 19, 2022ASSIGNED TO EXAMINER
Tuesday, August 30, 2022NON-FINAL ACTION WRITTEN
Tuesday, August 30, 2022NON-FINAL ACTION E-MAILED
Tuesday, August 30, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 28, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 28, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 1, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 10, 2023SUSPENSION LETTER WRITTEN
Monday, April 10, 2023LETTER OF SUSPENSION E-MAILED
Monday, April 10, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, December 20, 2023SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Thursday, March 7, 2024SUSPENSION INQUIRY WRITTEN
Thursday, March 7, 2024INQUIRY TO SUSPENSION E-MAILED
Thursday, March 7, 2024NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Thursday, March 14, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, March 14, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, March 15, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, March 15, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, March 15, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 9, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 9, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 9, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, November 6, 2024FINAL REFUSAL E-MAILED
Wednesday, November 6, 2024FINAL REFUSAL WRITTEN
Wednesday, November 6, 2024NOTIFICATION OF FINAL REFUSAL EMAILED

Related Keywords

inhibet disorders diseases pharmaceutical autoimmune related inflammatory preparations treating administration injection